Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Brotchie

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Rob M A de Bie, Tom H Johnston, et al.
Synapse (New York, N.Y.)|October 24, 2009
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primateMonty A Silverdale, Christopher Kobylecki, Penelope J Hallett, et al.
Behavioural Pharmacology|October 12, 2014
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned ratPhilippe Huot, Tom H Johnston, James B Koprich, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 17, 2005
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's diseaseMario van der Stelt, Susan H Fox, Michael Hill, et al.
Plos One|October 3, 2012
The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Michael N Gandy, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinationsPhilippe Huot, Tom H Johnston, Tayyeba Darr, et al.
Journal of Pharmaceutical Sciences|June 6, 2009
Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochlorideMatthew J McIldowie, Michael N Gandy, Brian W Skelton, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 28, 2008
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's diseaseNaomi P Visanji, Antonia Orsi, Tom H Johnston, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 16, 2012
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's diseasePhilippe Huot, Tom H Johnston, Naomi P Visanji, et al.
Neurobiology of Disease|August 31, 2014
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse modelsSherri L Thiele, Betty Chen, Charlotte Lo, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Movement Disorders : Official Journal of the Movement Disorder Society|September 2, 2008
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Rob M A de Bie, Tom H Johnston, et al.
Synapse (New York, N.Y.)|October 24, 2009
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primateMonty A Silverdale, Christopher Kobylecki, Penelope J Hallett, et al.
Behavioural Pharmacology|October 12, 2014
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned ratPhilippe Huot, Tom H Johnston, James B Koprich, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 17, 2005
A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's diseaseMario van der Stelt, Susan H Fox, Michael Hill, et al.
Plos One|October 3, 2012
The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Michael N Gandy, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinationsPhilippe Huot, Tom H Johnston, Tayyeba Darr, et al.
Journal of Pharmaceutical Sciences|June 6, 2009
Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochlorideMatthew J McIldowie, Michael N Gandy, Brian W Skelton, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 28, 2008
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's diseaseNaomi P Visanji, Antonia Orsi, Tom H Johnston, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 16, 2012
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's diseasePhilippe Huot, Tom H Johnston, Naomi P Visanji, et al.
Neurobiology of Disease|August 31, 2014
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse modelsSherri L Thiele, Betty Chen, Charlotte Lo, et al.
Pageof 13